All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the MPN Advocates Network.
The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by GSK, Novartis, Sobi and Takeda and supported through independent educational grants from Bristol Myers Squibb, Blueprint Medicines, Incyte and Merck Sharp & Dohme LLC, Rahway, NJ, USA. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account to access:
Bookmark & personalize site content
Receive alerts for new content in your areas of interest
View MPN content recommended for you
Jean-Jacques KiladjianDuring the 63rd ASH Annual Meeting and Exposition, the MPN Hub was pleased to speak to Jean-Jacques Kiladjian, Université de Paris and Hôpital Saint-Louis, Paris, FR. We asked, ASH2021: What are the key highlights in MPN?
ASH2021: What are the key highlights in MPN?
In this video, Kiladjian highlights the key advances presented at ASH, particularly in regard to MPN treatment. Kiladjian discusses the JAK2 inhibitor fedratinib and the FREEDOM (NCT03755518) and FREEDOM2 (NCT03952039) trials. He also mentions pelabresib and the MANIFEST (NCT02158858) trial. Lastly, he comments on the lysine-specific histone demethylase-1 (LSD1) inhibitor bomedemstat, CD123-targeting agent tagraxofusp, and AVID200, a transforming growth factor-beta (TGF-beta) inhibitor.
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
This content is accurate as of the date of publication and is not updated retrospectively. Please refer to the latest available evidence, guidelines, and relevant regulatory information when making clinical decisions.
Your opinion matters
Among patients with myelofibrosis and isolated anemia at presentation, with no indication for treatment with a JAK inhibitor, how often do you use anemia-directed treatments (EMAs, ESAs, danazol, etc.) as monotherapy?